Solbec Pharmaceuticals has received a positive international preliminary examination report on its manufacturing patent application for the method of separation of the key ingredient in its cancer fighting treatment.
The examiners found all 57 claims in Solbec’s application to be novel and have industrial applicability.
The positive examiners result follows the recent IPER on the company’s cancer receptor binding protein.
On that application the examiners found all 27 of Solbec’s claims were novel and had industrial application.
The applications were now moving into the national phases, with the company instructing its attorneys to lodge the Rhamnose Binding Protein patent application in Canada, Japan, China, Europe, New Zealand and India.
Applications in Australia and the US were filed some time ago and are pending.
Solbec managing director Stephen Carter said the positive IPERs were a major milestone for the company.
“As well as these applications, Solbec has two other new applications moving through the registration process and we are adding new applications to our portfolio,” he said.
Solbec’s leading anti-cancer compound, SBP002, is currently in Human Phase 1 clinical trials at Sir Charles Gairdner hospital.
